Optimization of small-molecule inhibitors of influenza virus polymerase: From thiophene-3-carboxamide to polyamido scaffolds

Journal of Medicinal Chemistry

Volumn 57, Issue 10, 2014, Pages 4337-4350

  Lepri, Susan ^a   Nannetti, Giulio ^b   Muratore, Giulia ^b   Cruciani, Gabriele ^a   Ruzziconi, Renzo ^a   Mercorelli, Beatrice ^b   Palù, Giorgio ^b   Loregian, Arianna ^b   Goracci, Laura ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[[5 (4 METHOXYPHENYL) 7 (TRIFLUOROMETHYL)PYRAZOLO[1,5 A]PYRIMIDIN 3 YL]CARBONYL]AMINO] 4,5,6,7 TETRAHYDROBENZO[B]THIOPHENE 3 CARBOXAMIDE; 2 [[[5 (4 TOLYL) 7 (DIFLUOROMETHYL)PYRAZOLO[1,5 A]PYRIMIDIN 3 YL]CARBONYL]AMINO] 4,5,6,7 TETRAHYDROBENZO[B]THIOPHENE 3 CARBOXAMIDE; 2 [[[5 PHENYL 7 (DIFLUOROMETHYL)PYRAZOLO[1,5 A]PYRIMIDIN 3 YL]CARBONYL]AMINO] 4,5,6,7 TETRAHYDROBENZO[B]THIOPHENE 3 CARBOXAMIDE; 2 [[[5 PHENYL 7 (TRIFLUOROMETHYL) [1,2,4]TRIAZOLO[1,5 A]PYRIMIDIN 3 YL]CARBONYL]AMINO] 4,5,6,7 TETRAHYDROBENZO[B]THIOPHENE 3 CARBOXAMIDE; 2 [[[5 PHENYL 7 (TRIFLUOROMETHYL)PYRAZOLO[1,5 A]PYRIMIDIN 3 YL]CARBONYL]AMINO] 4,5,6,7 TETRAHYDROBENZO[B]THIOPHENE 3 CARBOXAMIDE; 3 [2 (SEC BUTYLCARBAMOYL)PHENYLCARBAMOYL] 2 METHYL N (2,5 DIMETHYLPHENYL)BENZENESULFONAMIDE; 3 [2 (SEC BUTYLCARBAMOYL)PHENYLCARBAMOYL] N (4 HYDROXYPHENYL)BENZENESULFONAMIDE; 3 [2 (SEC BUTYLCARBAMOYL)PHENYLCARBAMOYL] N PHENYLBENZENESULFONAMIDE; 3 [N (2,5 DIMETHYLPHENYL)SULFAMOYL] 4 METHYL N [2 (PHENYLCARBAMOYL)PHENYL]BENZAMIDE; 5 [2 (SEC BUTYLCARBAMOYL)PHENYLCARBAMOYL] 2 METHYL N [(3 BENZAMIDO) PHENYLBENZENESULFONAMIDE; ANTIVIRUS AGENT; N (3 CARBOMOYL 5,6 DIHYDRO 4H CYCLOPENTA[B]THIOPHEN 2 YL) 5 PHENYL 7 (TRIFLUOROMETHYL)PYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; N (3 CARBOMOYL 5,6 DIHYDRO 4H CYCLOPENTA[B]THIOPHEN 2 YL) 7 (DIFLUOROMETHYL) 5 PHENYLPYRAZOLO[1,5 A]PYRIMIDINE 3 CARBOXAMIDE; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE INHIBITOR; THIOPHENE 3 CARBOXAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HEK293 CELL LINE; IN VITRO STUDY; INFLUENZA VIRUS; MDCK CELL LINE; MOLECULAR INTERACTION; NONHUMAN; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIVIRAL AGENTS; DOGS; DRUG DESIGN; HEK293 CELLS; HUMANS; MADIN DARBY CANINE KIDNEY CELLS; ORTHOMYXOVIRIDAE; RNA REPLICASE; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 84901255328     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500300r     Document Type: Article

References (62)

1. Harper, S. A.; Bradley, J. S.; Englund, J. A.; File, T. M.; Gravenstein, S.; Hayden, F. G.; McGeer, A. J.; Neuzil, K. M.; Pavia, A. T.; Tapper, M. L.; Uyeki, T. M.; Zimmerman, R. K. Seasonal influenza in adults and children - diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America Clin. Infect. Dis. 2009, 48, 1003-1032
2. Das, K. Antivirals targeting influenza A virus J. Med. Chem. 2012, 55, 6263-6277
3. Hurt, A. C.; Chotpitayasunondh, T.; Cox, N. J.; Daniels, R.; Fry, A. M.; Gubareva, L. V.; Hayden, F. G.; Hui, D. S.; Hungnes, O.; Lackenby, A.; Lim, W.; Meijer, A.; Penn, C.; Tashiro, M.; Uyeki, T. M.; Zambon, M. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives Lancet Infect. Dis. 2012, 12, 240-248
4. Moss, R. B.; Davey, R. T.; Steigbigel, R. T.; Fang, F. Targeting pandemic influenza: a primer on influenza antivirals and drug resistance J. Antimicrob. Chemother. 2010, 65, 1086-1093
5. Colman, P. M.; Varghese, J. N.; Laver, W. G. Structure of the catalytic and antigenic sites in influenza virus neuraminidase Nature 1983, 303, 41-44
6. Jackson, R. J.; Cooper, K. L.; Tappenden, P.; Rees, A.; Simpson, E. L.; Read, R. C.; Nicholson, K. G. Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review J. Infect. 2011, 62, 14-25
7. von Itzstein, M.; Wu, W. Y.; Kok, G. B.; Pegg, M. S.; Dyason, J. C.; Jin, B.; Van Phan, T.; Smythe, M. L.; White, H. F.; Oliver, S. W.; Colman, P. M.; Varghese, J. N.; Ryan, D. M.; Woods, J. M.; Bethell, R.; Hotham, V. J.; Cameron, J. M.; Penn, C. R. Rational design of potent sialidase-based inhibitors of influenza virus replication Nature 1993, 363, 418-423
8. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules J. Med. Chem. 1985, 28, 849-857
9. Samson, M.; Pizzorno, A.; Abed, Y.; Boivin, G. Influenza virus resistance to neuraminidase inhibitors Antiviral Res. 2013, 98, 174-185
10. Loregian, A.; Mercorelli, B.; Nannetti, G.; Compagnin, G.; Palù, G. Antiviral strategies against influenza virus: towards new therapeutic approaches. Cell. Mol. Life Sci. 2014, [Online early access]. DOI 10.1007/s00018-014-1615-2.
11. Suzuki, T.; Ainai, A.; Nagata, N.; Sata, T.; Sawa, H.; Hasegawa, H. A novel function of the N-terminal domain of PA in assembly of influenza A virus RNA polymerase Biochem. Biophys. Res. Commun. 2011, 414, 719-726
12. Yamada, K.; Koyama, H.; Hagiwara, K.; Ueda, A.; Sasaki, Y.; Kanesashi, S. N.; Ueno, R.; Nakamura, H. K.; Kuwata, K.; Shimizu, K.; Suzuki, M.; Aida, Y. Identification of a novel compound with antiviral activity against influenza A virus depending on PA subunit of viral RNA polymerase Microbes Infect. 2012, 14, 740-747
13. Muratore, G.; Goracci, L.; Mercorelli, B.; Foeglein, á.; Digard, P.; Cruciani, G.; Palù, G.; Loregian, A. Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 6247-6252
14. Muratore, G.; Mercorelli, B.; Goracci, L.; Cruciani, G.; Digard, P.; Palù, G.; Loregian, A. The human cytomegalovirus inhibitor AL18 also possesses activity against influenza A and B viruses Antimicrob. Agents Chemother. 2012, 56, 6009-6013
15. Kessler, U.; Castagnolo, D.; Pagano, M.; Deodato, D.; Bernardini, M.; Pilger, B.; Ranadheera, C.; Botta, M. Discovery and synthesis of novel benzofurazan derivatives as inhibitors of influenza A virus Med. Chem. Lett. 2013, 23, 5575-5577
16. Massari, S.; Nannetti, G.; Goracci, L.; Sancineto, L.; Muratore, G.; Sabatini, S.; Manfroni, G.; Mercorelli, B.; Cecchetti, V.; Facchini, M.; Palù, G.; Cruciani, G.; Loregian, A.; Tabarrini, O. Structural investigation of cycloheptathiophene-3-carboxamide derivatives targeting influenza virus polymerase assembly J. Med. Chem. 2013, 56, 10118-10131
17. Pagano, M.; Castagnolo, D.; Bernardini, M.; Fallacara, A. L.; Laurenzana, I.; Deodato, D.; Kessler, U.; Pilger, B.; Stergiou, L.; Strunze, S.; Tintori, C.; Botta, M. The Fight against the influenza A virus H1N1: synthesis, molecular modeling, and biological evaluation of benzofurazan derivatives as viral RNA polymerase inhibitors Chem. Med. Chem. 2014, 9, 129-150
18. Tintori, C.; Laurenzana, I.; Fallacara, A. L.; Kessler, U.; Pilger, B.; Stergiou, L.; Botta, M. High-throughput docking for the identification of new influenza A virus polymerase inhibitors targeting the PA-PB1 protein-protein interaction Bioorg. Med. Chem. Lett. 2014, 24, 280-282
19. Palese, P.; Shaw, M. L. Orthomyxoviridae: The viruses and their replication. In Fields Virology, 5 th ed.; Knipe, D. M.; Howley, P. M., Eds.; Lippencott Williams and Wilkins: Philadelphia, PA, 2007; Vol. 2, pp 1647-1689.
20. Horisberger, M. A. The large P proteins of influenza A viruses are composed of one acidic and two basic polypeptides Virology 1980, 107, 302-305
21. Nagata, K.; Kawaguchi, A.; Naito, T. Host factors for replication and transcription of the influenza virus genome Rev. Med. Virol. 2008, 18, 247-260
22. Palù, G.; Loregian, A. Inhibition of herpesvirus and influenza virus replication by blocking polymerase subunit interactions Antiviral Res. 2013, 99, 318-327
23. Obayashi, E.; Yoshida, H.; Kawai, F.; Shibayama, N.; Kawaguchi, A.; Nagata, K.; Tame, J. R.; Park, S. Y. The structural basis for an essential subunit interaction in influenza virus RNA polymerase Nature 2008, 454, 1127-1131
24. N complex from an avian influenza H5N1 virus Nature 2008, 454, 1123-1126
25. Sugiyama, K.; Obayashi, E.; Kawaguchi, A.; Suzuki, Y.; Tame, J. R.; Nagata, K.; Park, S. Y. Structural insight into the essential PB1-PB2 subunit contact of the influenza virus RNA polymerase EMBO J. 2009, 28, 1803-1811
26. Reuther, P.; Mänz, B.; Brunotte, L.; Schwemmle, M.; Wunderlich, K. Targeting of the influenza A virus polymerase PB1-PB2 interface indicates strain-specific assembly differences J. Virol. 2011, 85, 13298-13309
27. Kessler, U.; Mayer, D.; Wunderlich, K.; Rnadheera, C.; Schwemmle, M. Influenza A and B virus replication-inhibiting peptides. U.S. Patent 0129764, May 24, 2012.
28. Ghanem, A.; Mayer, D.; Chase, G.; Tegge, W.; Frank, R.; Kochs, G.; García-Sastre, A.; Schwemmle, M. Peptide-mediated interference with influenza A virus polymerase J. Virol. 2007, 81, 7801-7804
29. Scognamiglio, P. L.; Di Natale, C.; Perretta, G.; Marasco, D. From peptides to small molecules: an intriguing but intricated way to new drugs Curr. Med. Chem. 2013, 20, 3803-3817
30. Hagmann, W. K. The many roles for fluorine in medicinal chemistry J. Med. Chem. 2008, 51, 4359-4369
31. Filler, R.; Saha, R. Fluorine in medicinal chemistry: a century of progress and a 60-year retrospective of selected highlights Future Med. Chem. 2009, 1, 777-791
32. Purser, S.; Mooreb, P. R.; Swallow, S.; Gouverneur, V. Fluorine in medicinal chemistry Chem. Soc. Rev. 2008, 37, 320-330
33. 3 analogs J. Synth. Org. Chem. Jpn. 1985, 43, 1073-1082
34. 1A ligands Bioorg. Med. Chem. Lett. 2004, 14, 1709-1712
35. Böhm, H. J.; Banner, D.; Bendels, S.; Kansy, M.; Kuhn, B.; Müller, K.; Obst-Sander, U.; Stahl, M. Fluorine in medicinal chemistry ChemBioChem 2004, 5, 637-643
36. Smart, B. E. Fluorine substituent effects (on bioactivity) J. Fluorine Chem. 2001, 109, 3-11
37. 1D receptor ligands with improved pharmacokinetic profiles J. Med. Chem. 1999, 42, 2087-2104
38. 3 Am. J. Physiol. 1983, 244, E159-163
39. Abbate, F.; Casini, A.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the perfluorobenzoyl analogue of methazolamide. Implications for the drug design of fluorinated inhibitors J. Enzyme Inhib. Med. Chem. 2003, 18, 303-308
40. Zhang, W.; Wang, F.; Hu, J. N -tosyl- S -difluoromethyl- S -phenylsulfoximine: a new difluoromethylation reagent for S-, N-, and C-nucleophiles Org. Lett. 2009, 11, 2109-2112
41. Baroni, M.; Cruciani, G.; Sciabola, S.; Perruccio, F.; Mason, J. S. A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for Ligands And Proteins (FLAP): theory and application J. Chem. Inf. Model 2007, 47, 279-294
42. Goodford, P. J. The Basic Principles of GRID. In Molecular Interaction Fields: Applications in Drug Discovery and ADME Prediction; Cruciani, G., Ed.; Wiley-VCH: Weinheim, Germany, 2006; pp 1-25.
43. Gewald, K.; Schinke, E.; Böttcher, H. Heterocyclen aus CH-aciden Nitrilen, VIII. 2-amino-thiophene aus methylenaktiven nitrilen, carbonylverbindungen und schwefel Chem. Ber. 1966, 99, 94-100
44. Yoshida, M.; Mori, A.; Inaba, A.; Oka, M.; Makino, H.; Yamaguchi, M.; Fujita, H.; Kawamoto, T.; Goto, M.; Kimura, H.; Baba, A.; Yasuma, T. Synthesis and structure-activity relationship of tetrahydropyrazolopyrimidine derivatives-A novel structural class of potent calcium-sensing receptor antagonists Bioorg. Med. Chem. 2010, 18, 8501-8511
45. Asano, T.; Yoshikawa, T.; Usui, T.; Yamamoto, H.; Yamamoto, Y.; Uehara, Y.; Nakamura, H. Benzamides and benzamidines as specific inhibitors of epidermal growth factor receptor and v-Src protein tyrosine kinases Bioorg. Med. Chem. 2004, 12, 3529-3542
46. Bunnett, J. F.; Naff, M. B. Kinetics of reactions of amines with isatoic anhydride J. Am. Chem. Soc. 1966, 88, 4001-4008
47. Graham, S. L.; Hoffman, J. M.; Gautheron, P.; Michelson, S. R.; Scholz, T. H.; Schwam, H.; Shepard, K. L.; Smith, A. M.; Smith, R. L.; Sondey, J. M.; Sugrue, M. F. Topically active carbonic anhydrase inhibitors. 3. Benzofuran- and indole-2-sulfonamides J. Med. Chem. 1990, 33, 749-754
48. Graham, S. L.; Scholz, T. H. The reaction of sulfinic acid salts with hydroxylamine- O -sulfonic acid. A useful synthesis of primary sulfonamides Synthesis 1986, 12, 1031-1032
49. Mullin, A. E.; Dalton, R. M.; Amorim, M. J.; Elton, D.; Digard, P. Increased amounts of the influenza virus nucleoprotein do not promote higher levels of viral genome replication J. Gen. Virol. 2004, 85, 3689-3698
50. Sidwell, R. W.; Huffman, J. H.; Khare, G. P.; Allen, L. B.; Witkowski, J. T.; Robins, R. K. Broad-spectrum antiviral activity of Virazole: 1-Beta-Dribofuranosyl-1,2,4-triazole-3-carboxamide Science 1972, 177, 705-706
51. Liu, H.; Yao, X. Molecular basis of the interaction for an essential subunit PA-PB1 in influenza virus RNA polymerase: Insights from molecular dynamics simulation and free energy calculation Mol. Pharmaceutics 2010, 7, 75-85
52. Loregian, A.; Rigatti, R.; Murphy, M.; Schievano, E.; Palù, G.; Marsden, H. S. Inhibition of human cytomegalovirus DNA polymerase by C-terminal peptides from the UL54 subunit J. Virol. 2003, 77, 8336-8344
53. Loregian, A.; Coen, D. M. Selective anti-cytomegalovirus compounds discovered by screening for inhibitors of subunit interactions of the viral polymerase Chem. Biol. 2006, 13, 191-200
54. 1H NMR to facilitate solubility measurement for drug discovery compounds Int. J. Pharm. 2009, 369, 47-52
55. Kansy, M.; Senner, F.; Gubernator, K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes J. Med. Chem. 1998, 41, 1007-1010
56. Cross, S.; Baroni, M.; Goracci, L.; Cruciani, G. GRID-based three-dimensional pharmacophores I: FLAPpharm, a novel approach for pharmacophore elucidation J. Chem. Inf. Model. 2012, 52, 2587-2598
57. a prediction method using grid molecular interaction fields J. Chem. Inf. Model. 2007, 47, 2172-2181
58. a prediction and ADME profiling Chem. Biodivers. 2009, 6, 1812-1821
59. Offermann, W.; Eger, K.; Roth, H. J. Synthesis of bicyclic 1,2,6-thiadiazines Arch. Pharm. 1981, 314, 168-175
60. Perrissin, M.; Favre, M.; Luu-Duc, C.; Bakri-Logeais, F.; Huguet, F.; Narcisse, G. Thieno[2.3-d]-4-pyrimidones: synthesis, structure and pharmacological properties Eur. J. Med. Chem. 1984, 19, 420-424
61. Loregian, A.; Appleton, B. A.; Hogle, J. M.; Coen, D. M. Residues of human cytomegalovirus DNA polymerase catalytic subunit UL54 that are necessary and sufficient for interaction with the accessory protein UL44 J. Virol. 2004, 78, 158-167
62. Loregian, A.; Appleton, B. A.; Hogle, J. M.; Coen, D. M. Specific residues in the connector loop of the human cytomegalovirus DNA polymerase accessory protein, UL44, are crucial for interaction with the UL54 catalytic subunit J. Virol. 2004, 78, 9084-9092